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The study compared the outcome in patients with advanced colonic cancer at high risk of peritoneal metastases (mucinous or
signet-ring cell) without peritoneal or systemic spread, treated with standard colectomy or a more aggressive combined surgical
approach. The study included patients with colonic cancer with clinical T3/T4, any N, M0, and mucinous or signet ring cell
histology. The 25 patients in the experimental group underwent hemicolectomy, omentectomy, bilateral adnexectomy, hepatic
round ligament resection, and appendectomy, followed by HIPEC. The control group comprised 50 patients treated with standard
surgical resection during the same period in the same hospital by diﬀerent surgical teams. Outcome data, morbidity, peritoneal
recurrence rate, and overall, and disease-free survival, were compared. Peritoneal recurrence developed in 4% of patients in the
experimental group and 22% of controls without increasing morbidity (P<0.05). Actuarial overall survival curves disclosed no
signiﬁcant diﬀerences, whereas actuarial disease-free survival curves showed a signiﬁcant diﬀerence between groups (36.8 versus
21.9 months, P<0.01). A more aggressive preventive surgical approach combined with HIPEC reduces the incidence of peritoneal
recurrence in patients with advanced mucinous colonic cancer and also signiﬁcantly increases disease-free survival compared with
a homogeneous control group treated with a standard surgical approach without increasing morbidity.
1.Introduction
Epidemiological data indicate that peritoneal spread from
colorectal cancer is an event that involves 10–15% of patients
at the time of primary cancer resection and about 25–50%
of patients with recurrent disease, generally leading to death
within weeks or months [1–5] .S e v e r a lf e a t u r e so fp r i m a r y
tumors of colorectal origin appear to be related to a later
development of peritoneal spread: mucinous colorectal can-
cers or signet ring cell carcinomas tend preferentially to me-
tastasizetotheperitoneumorovaries[6–10].Intraperitoneal
metastases may spread by full-thickness bowel wall invasion
or may arise iatrogenically during surgery when “in transit”
tumor cells or emboli escape from dissected lymph vessels
within the bowel lumen or reach the peritoneal cavity
through blood spill from the surgical ﬁeld [11].
Since the 1990s, Paul Sugarbaker’s studies on cytoreduc-
tive surgery plus perioperative intraperitoneal chemother-
apy such as hyperthermic intraperitoneal chemotherapy
( H I P E C )h a v ep r o m p t e dan e wt r e a t m e n to p t i o nf o rs e l e c t e d
pa-tients with peritoneal metastases from colorectal cancer
[12–14]. Three studies, one randomized and two nonran-
domized, haveshownthatthis combinedprocedureprovides
abetteroutcomethan5-ﬂuorouracil-basedchemotherapyor
more modern chemotherapy regimens [15–17].
Despite these encouraging results, even if 5-year survival
can reach a value close to 45% at the expense of a mortality
rate ranging from 3 to 5% and a morbidity rate around 30%2 Gastroenterology Research and Practice
in selected cases [18, 19], outcome depends on many factors.
T h eﬁ r s ti sp e r i t o n e a li n v o l v e m e n ta sm e a s u r e db yt h ep e r i -
toneal cancer index (PCI), the second the degree of cytore-
duction achieved, and ﬁnally the surgical team’s level of
experience [20, 21]. Given that better prognostic results can
be expected only in patients with a low PCI, in whom com-
plete cytoreduction is possible, and because current imaging
techniques cannot detect peritoneal metastases before they
becomes clinically evident and symptomatic [22, 23], in
practice these combined approaches apply only to few
patients and rarely oﬀer long-term survival.
In the past, in line with what others now propose for
ovarian cancer [24], experimental investigations and clinical
trials have used normothermic intraperitoneal chemother-
apyasadjuvanttreatmentincolorectalpatientsathighriskof
recurrence,withinconclusiveresults[25–27].Inrecentyears,
some have suggested early second-look surgery in the ab-
sence of clinical signs of recurrence for colorectal patients
at high risk of peritoneal relapse to detect and treat those
with carcinomatosis at an initial stage [28, 29]. Based on
preliminary results, two randomized trials will begin in
France and the United States to answer the question whether
second-look surgery envisaging cytoreductive surgery with
H I P E Co rH I P E Ca l o n ew i l lp r o l o n go v e r a l ls u r v i v a la n d
reduce the risk of relapse compared with standard care (ob-
servation) in patients with colorectal cancer at high risk for
peritoneal spread [30, 31].
Prompted by the need to seek new ways of managing
colorectal cancer in patients at high risk of recurrence but
still without evident signs of peritoneal spread, we decid-
ed to concentrate our eﬀorts on a timely strategy envisaging
a primary operation aimed at preventing peritoneal metas-
tases. Ample evidence shows that the two major elements in-
ﬂuencing peritoneal spread in colorectal cancer are the depth
of bowel wall invasion (pT3/4) and histological features of
the malignancy (mucinous and signet ring cell carcinomas)
[5–11]. Both are characteristics that the surgeon can verify
during the primary operation and if necessary use the in-
formation to change the strategy to a more aggressive ap-
proach combining surgical resection and HIPEC.
We designed this single-center case-control study to an-
alyzeoutcomeintwocomparablegroupsofpatientswithad-
vanced colonic cancer (pT3/4 with mucinous or signet ring
cell cancer) without peritoneal or systemic spread treated
with standard colectomy, according to the established guide-
lines [32] (control group), or by a more aggressive combined
approach aimed to prevent peritoneal spread. For this pur-
pose, in the experimental group we extended our standard
sur-gical resection to the metastatic sanctuaries of peritoneal
diﬀusion (including the omentum, adnexa, and appendix)
and combined these surgical procedures with prophylactic
HIPEC. As the primary outcome variables we compared
morbidity, the incidence of peritoneal recurrence and overall
and disease-free survival in the two groups.
2.MaterialsandMethods
2.1. Experimental Group. The study included patients with
colonic cancer or intraperitoneal rectosigmoid cancer (over
15cm from the anal verge) with clinical T3/T4, any N, and
M0 stage treated at the Department of Surgery Pietro Val-
doni at Sapienza University of Rome from January 2006 to
December 2008. To avoid bias from neoadjuvant therapy we
excluded patients with extraperitoneal rectal cancer. Selec-
tion criteria were age younger than 70 years, cancer with
mucinousorsignetringcellcomponents(>20%accordingto
criteria proposed by Ogino et al. [33], performance status
0–2 (WHO) [34]), and adequate renal, hepatic, and bone
marrow function. All patients gave speciﬁc informed written
consent. Exclusion criteria were metastatic disease, other
malignances, multiple colorectal cancer, active infections, or
severe associated medical conditions. Patients with perfo-
rated cancers were considered eligible regardless of histology.
At surgical exploration, patients with unrecognized peri-
toneal seedings were excluded from the study as well as those
with hepatic involvement detected at intraoperative ultra-
sound. None of the patients underwent peritoneal lavage
cytology [35]. At operation, after the standard hemicolec-
tomy done according to the established guidelines, intraop-
erative pathologic evaluation assessed tumor depth (pT) and
the histologic features necessary to include the patient in the
study. In the selected cases the surgical resection also includ-
ed complete omentectomy, bilateral adnexectomy in post-
menopausal patients, hepatic round ligament resection and
appendectomy if not already done. At the end of surgery,
HIPEC was delivered with the closed technique with oxali-
platin 460mg/m2 in 2l/m2 of dextrose at a temperature of
43◦Cover30minutesataﬂowrateof2L/min.BeforeHIPEC
began and during surgery patients received intravenous ﬂu-
orouracil of 400mg/m2 a n dl e u c o v o r i no f2 0m g / m 2 to po-
tentiate oxaliplatin activity. Systemic adjuvant chemotherapy
was reserved after discharge to patients with pT4, node posi-
tive, and G3 tumors. The study was approved by the hospital
institutional review board.
2.2. Control Group. Control subjects were retrospectively
selected from patients with colonic cancer treated with stan-
dard surgical resection, during the same period in the same
hospitalbutbydiﬀerentsurgicalteams.Theselectionprocess
comprised two steps. During the ﬁrst step surgeons from
another surgical team in our hospital selected from their re-
cords all patients with colonic cancer treated from January
2006 to December 2008 and who met the eligibility criteria
required in our experimental study and had known follow-
up. In particular, we selected patients with T3/T4 mucinous
or signet ring cell carcinoma resected for cure (R0) without
systemic spread. As in the experimental group, control
patients with perforated colon cancer were included regard-
less of histology. During the second step the principal in-
vestigator (P. Sammartino) double-checked the medical re-
cords for the potentially eligible patients provided by other
surgical teams by recontacting the investigator to ensure that
theeligibilitycriteriahadbeenhomogeneouslyapplied.Dur-
ing double-checking the investigator was unaware of the pa-
tients’ outcome.
2.3. Follow-Up and Statistics. Data for patients in the exper-
imental group were recorded prospectively in a speciﬁcGastroenterology Research and Practice 3
database. Data for patients the control group were recorded
retrospectively. Surgical complications and adverse events
were monitored in both groups and graded from 0 to V
in accordance with the National Cancer Institute Common
Toxicity Criteria [36]. Follow-up assessments took place
every 3 months with clinical evaluation and tumor marker
monitoring. A 64-section multidetector computed tomogra-
phy (MDCT) and magnetic resonance imaging (MRI) with
conventional and diﬀusion-weighted sequences were ob-
tained alternatively every 6 months in the experimental and
control groups, according to a protocol developed in collab-
oration with a dedicated radiological team [37]. The deﬁ-
nition of peritoneal recurrence, included imaging ﬁndings
of locoregional progression as well as peritoneal metastases
distant from the resection site. No patient was excluded from
the survival analysis. The chi-square test was used for uni-
variate comparison. Survival curves were calculated with the
Kaplan-Meier method and compared with the log-rank test.
Survival was measured from the date of surgical treatment
until death or the last follow-up. P values < 0.05 were con-
sidered to indicate statistical signiﬁcance.
3. Results
Of the 230 patients with colonic cancer treated in our
department between January 2006 and December 2008,
25 fulﬁlled the inclusion criteria and agreed to take part
in this experimental investigation. A total of 75 patients
were proposed for matching with those in the experimental
study and after double checking for eligible criteria 50 were
included in the control group. The clinical characteristics
for both groups are shown in Table 1.S u r g i c a lp r o c e d u r e s
p e r f o r m e di nb o t hg r o u p sa r er e p o r t e di nTable 2.
When surgery ended all 25 patients in the experimental
group underwent HIPEC. In the study group a mean of 20
lymph nodes per patient were removed (range 15–28) and in
the control group a mean of 19 (range 14–31). Locoregional
lymph node metastases were found in 34% of patients in
the experimental group and in 28% of those in the control
group. Anatomopathological studies in the experimental
group showed that none of the surgical specimens excised
according to the protocol contained malignant disease. All
the surgical procedures in both groups were R0. The mean
length of surgery, blood loss, and postoperative stay were
similar in the two groups. Except for 1 patient in the ex-
perimental group who had grade 2 pancreatitis related to
HIPEC toxicity (that promptly regressed after medical thera-
py) morbidity rates were similar in the two groups. One
patientintheexperimentalgroupunderwentemergencylap-
arotomy on postoperative day 2 for bleeding. One patient in
the control group had a grade III complication (left ureteral
leakage) that required endoscopy to place a stent, and 3
patients underwent a second laparotomy to construct an
ileostomy for anastomotic leakage (Table 3). A total of 13
patients in the experimental group (52%) and 23 in the con-
trol group (46%) underwent ﬁrst-line systemic adjuvant
chemotherapy with ﬂuorouracil and oxaliplatin. In relapsed
patients second-line chemotherapy included irinotecan or
Table 1: Clinical characteristics of the 2 groups.
Patients (25) Controls (50)
Mean age 62 (45–70) Mean age 63 (48–72)
N % N %
Sex
Male 16 66 31 62
Female 9 34 19 38
Performance status
02 1 8 4 4 1 8 2
14 1 6 7 1 4
2— — 2 4
Tumor site
Right colon 9 36 15 30
Transverse colon 3 12 6 12
Left colon 13 52 29 58
Pt
pT3 19 76 40 80
p T 4 a 14 12
pT4b 5 20 9 18
Nodal status
N0 16 66 36 72
N1-2 9 34 14 28
Grading
G2 17 68 37 64
G3 8 32 13 26
Histology
Mucinous 23 92 45 90
S i g n e t r i n g c e l l 14 48
Adc nos 1∗ 41 ∗ 2
∗Perforated patients.
molecular target drugs (cetuximab and bevacizumab or
both).
3.1. Follow-Up. After a mean 37.8-month follow-up in the
experimental group and 35.1 months in the control group,
24% in the experimental group and 32% of the controls had
recurrent disease (Table 4).
3.2. Experimental Group. Six patients showed relapse of
disease: 5 had hepatic and or pulmonary metastases (mean
time of recurrence 13 months) and 1 developed a peritoneal
recurrence. This patient underwent a right hemicolectomy
with abdominal wall resection for a T4b tumour and expe-
rienced a peritoneal recurrence detected at 30 months after
operation. Two patients (one with single hepatic metastases
and the peritoneal recurrence) underwent a second surgical
procedure and are at the moment alive and disease-free at
38 and 39 months. Of the other 4 patients, 1 is currently
alivewithhepaticandpulmonarymetastasesand3diedfrom
progressive disease at a mean of 21 months.4 Gastroenterology Research and Practice
Table 2: Surgical procedures performed in the 2 groups.
Patients Controls
Surgical procedures
Complete omentectomy 25∗ —
Hepatic round ligament resection 25∗ —
Left hemicolectomy 13 29
Appendectomy 10∗ —
Right hemicolectomy 9 15
Bilateral adnexectomy 6∗ 1◦§
Transverse colon resection 3 6
Cholecystectomy 2§ 2§
Abdominal wall resection 2◦ 3◦
Small bowel resection 2◦ 3◦
Right adnexectomy 1∗ 1◦
Hysterectomy 1§ 1◦
Total, mean per patient 99–3.9 61–1.2
∗Procedures performed according to the study protocol.
◦Procedures performed for the tumor direct invasion.
§Procedures performed for the coexisting benign disease.
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Figure 1: Overall survival.
3.3. Control Group. Sixteen patients showed recurrent dis-
ease: a peritoneal recurrence was found in 11 (22%), associa-
ted in 4 cases with hepatic and/or pulmonary disease at
a mean of 12.7 months after ﬁrst operation. Initial dia-
gnosis of peritoneal metastases was made after MDCT and
MRI ﬁndings according to our published protocol [37]. In 9
patients the diagnosis was also conﬁrmed by endoperitoneal
ascites cytology or histology during laparoscopy or opera-
tion. Five patients showed only a systemic progression of
the disease (hepatic in 3, pulmonary in 1, and both in 1).
Three patients underwent a second surgical procedure:
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Figure 2 :D i s e a s ef r e es u r v i v a l .
1 underwent a wedge resection for a single hepatic metastasis
(alive disease-free at 31 months) and 2 cytoreduction and
HIPEC for peritoneal metastases (alive with disease at 26 and
24months).Fourpatientsarecurrentlyalivewithdiseaseand
9 died from progression at a mean of 15.6 months.
A statistically signiﬁcant diﬀerence in development of
peritoneal metastases was observed between the 2 groups
(P<0.05, Table 4). The actuarial overall survival curves dis-
close no signiﬁcant diﬀerence between the two groups
(Figure 1) whereas the actuarial disease-free survival curves
already show a signiﬁcant diﬀerence (P<0.01) between the
two groups (36.8 months in the experimental group versus
21.9 months in the control group, Figure 2).
4. Discussion
Our preliminary results in this single-center case-control
study show that our more aggressive preventive surgical ap-
proach combined with HIPEC signiﬁcantly reduces the
incidence of peritoneal recurrence in patients with advanced
mucinous colonic cancer and also signiﬁcantly increases dis-
ease-free survival compared with a homogeneous control
group treated with a standard surgical approach and does so
without increasing morbidity. Although our current data for
o v e r a l ls u r v i v a ls e e ma sy e tt os h o wn od i ﬀerence between
the survival curves for the experimental group and controls,
thesigniﬁcantdiﬀerenceindisease-freesurvivalsuggeststhat
o v e r a l ls u rvi v a lwi l le v e n t u a l l yd i ﬀer as follow-up progresses.
Our preventive surgical strategy could have improved
outcome because it is based on current knowledge on peri-
toneal ﬂuid dynamics showing that exfoliated tumor cells
from full-thickness tumors especially those from mucinous
histotypes colonize speciﬁc sites [38, 39]. According toGastroenterology Research and Practice 5
Table 3: Surgical outcome in the 2 groups.
Morbidity Patients Controls
N % N %
Grade I/II 3 12 5 10
Grade III — — 1 2
Grade IV 1 4 3 6
Hipec tox. grade 2 1∗ 4— —
Patients Controls
Mean operation time (min) 180 (120–210) 155 (90–220)
Mean blood loss (mL) 210 (180–290) 230 (150–400)
Postop. stay (days) 11 (8–14) 14 (8–21)
∗Pancreatic.
Table 4: Site of recurrence.
Patients (25) Controls (50) P
Metastases N % N %
Distant 5 20 9 18 ns
Peritoneal 1 4 11∗ 22 <0.05
Total 6 24 16 32 ns
∗4 patients had also distant metastases.
a series of well-documented events, as in ovarian cancer pro-
gression, malignant spread in colonic cancer preferentially
targetstheomentum,pelvis,andileocecalregions.Removing
thesetargetorgansattheﬁrstsurgicalinterventionregardless
of whether they are macroscopically involved and following
these surgical procedures with HIPEC, both aimed to
eradicate microscopic residual disease, seems a reasonable
strategy to reduce peritoneal spread.
Wecannotsaywhetherthereducedperitonealrecurrence
and signiﬁcantly improved disease-free survival in the exper-
imental group depend on the associated surgical procedures
(omentectomy, adnexectomy, appendectomy, and round
ligament resection) or on HIPEC. Although pathological
studies of the anatomic structures preventively removed in
our patients disclosed no evidence of malignant disease, we
can reasonably presume that removing these structures and
delivering HIPEC both contributed to preventing micro-
scopic peritoneal diﬀusion [40, 41].
Our proposal to address the problem from a new angle,
namely, preventing colorectal peritoneal spread, seems to
oﬀer a promising alternative to those who recommend an
early second look in high-risk patients [28, 31]. In our pre-
ventive study we deﬁned high-risk patients with advanced
colonic cancer as those with pT3/4 mucinous or signet ring
cell cancer without peritoneal or systemic spread whereas
those proposing second-look surgery enrolled a varied pop-
ulation including patients who at the primary intervention
alreadyhadlimitedperitonealcarcinomatosisorovarianme-
tastases [28, 31]. These nonhomogeneous populations will
make it diﬃcult to interpret outcomes in the two ongoing
randomizedtrialsinvestigating second-looksurgery[30,31].
A major concern is whether randomizing patients to second-
look surgery or observation is ethically justiﬁable given
that in a preliminary report Elias et al. at second-look
found that more than 50% of high-risk patients had peri-
toneal carcinomatosis that clinical and imaging examination
left unrecognized [28]. Lastly, another problem related to
second-look surgery is that a whole class of patients (those
termed at high risk) must be referred to highly specialized
tertiary centers (peritoneal surface malignancy treatment
centers) so that peritoneal carcinomatosis if found can be
properly treated. As cancer surgeons well know, the medical
community still regards integrated treatments for peritoneal
carcinomatosis with skepticism. And we all know how dif-
ﬁcult it is to persuade patients (and their oncologist) to un-
dergo a second intervention that may be lengthy and not
without risks in the absence of speciﬁc symptoms and
documentable clinical evidence. From the viewpoint of fea-
sibility and costs we therefore consider it more appropriate
to concentrate our eﬀorts on and invest our resources in
preventing peritoneal carcinomatosis right from the primary
operation. If our innovative preventive strategy proves
therapeutically worthwhile then it could be done in a larger
number of surgical centers, would involve a larger number
of patients, and might ﬁnally change the therapeutic options
available to patients with advanced colorectal cancer at risk
for peritoneal carcinomatosis [29].
Some might criticize our preventive proposal stating that
in patients with advanced colonic cancer with no documen-
ted signs of carcinomatosis our aggressive approach could
be considered overtreatment. This criticism notwithstand-
ing, our early aggressive approach receives strong support
because without increasing morbidity rates it lowers the in-
cidence of peritoneal carcinomatosis and oﬀers better dis-
ease-free survival than in a homogeneous sample of patients
whoreceivedstandardsurgicaltreatment.Ourpreventiveap-
proach also accords with Sugarbaker, who recommended
after second-look surgery negative for carcinomatosis a pro-
cedure analogous to the one we describe here (omentectomy,
adnexectomy, and HIPEC) [29]. Hence, in high-risk patients
why not use this approach right from the primary surgical
intervention. The true therapeutic value of our preventive
surgical approach for patients with advanced mucinous
colonic cancer awaits conﬁrmation in future randomized
multicenter studies.6 Gastroenterology Research and Practice
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